Takeda Pharmaceutical Co. Ltd. agreed to codevelop and commercialize up to three of Innovent Biologics Co. Ltd.’s immuno-oncology (I-O) and antibody-drug conjugate (ADC) candidates with the signing of ...
German Merck KGaA’s recently acquired subsidiary SpringWorks Therapeutics today announced that long-term efficacy and safety data from the Phase III DeFi trial of Ogsiveo (nirogacestat) were in the ...
Long-term continuous OGSIVEO treatment for up to 4 years was associated with further tumor size reductions, increase in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback